Alterations in cadherin and catenin expression during the biological progression of melanocytic tumours

D S A Sanders, K Blessing, G A R Hassan, R Bruton, J R Marsden, J Jankowski

Abstract

Aims—Compelling evidence from cell culture studies implicates cadherins in the neoplastic progression of melanocytic tumours but few reports describe the expression of cadherins and the related transmembrane proteins, catenins, in a full range of benign and malignant excised melanocytic tumours.

Methods—Using immunohistochemistry and western blotting after tissue fractionation, the pattern of expression of cadherins/catenins was studied in a range of surgically excised melanocytic tumours, from dysplastic naevi to stage III cutaneous metastatic malignant melanoma.

Results—Appropriate membranous expression of E-cadherin and P-cadherin is seen in dysplastic naevocytes with an epithelioid phenotype and is largely maintained with malignant transformation to radial growth phase melanoma and primary vertical growth phase malignant melanoma. Loss of membranous E-cadherin is seen in a small number of vertical growth phase melanomas only when metastasis has occurred. However, there is a concomitant dramatic loss of membranous P-cadherin expression in all melanomas at the same stage. A minority of metastatic melanomas show de novo membranous N-cadherin expression in comparison with dysplastic naevi and primary melanoma. Membranous expression of the desmosomal cadherin, desmoglein, was not seen in any tumour studied. Frequently, β catenin is aberrantly produced in the cytoplasm of cells in dysplastic naevi and metastatic malignant melanoma, with an implied compromise to adhesive function. Furthermore, membranous γ catenin expression was not seen in any of the 70 melanocytic tumours studied, implying obligatory transmembrane binding of cadherins to β catenin for maintenance of adhesive function.

Conclusions—The most important alterations in membranous cadherin and catenin expression are seen late in the biological progression of melanocytic tumours at the stage of “in transit” or regional lymph node metastasis, with implications for tumour growth, invasion, and dissemination.

(J Clin Pathol: Mol Pathol 1999;52:151–157)

Keywords: cadherin; catenin; melanoma

Melanoma often develops from clinically and histologically well defined precursor lesions.1 Expression of different families of adhesion molecules has been reported previously in melanoma,2–4 with major changes reported in the progression of normal melanocytes to benign naevi. Further dramatic changes also occur when cells progress from dysplastic naevi or radial growth phase melanoma to biologically late vertical growth phase primary melanoma.5–6

There is now compelling evidence to suggest that cadherins play a major role in epithelial cell–cell adhesion, with additional key roles recognised for cell phenotype, differentiation, epithelial/mesenchymal transformation, and invasion.7–11 Loss of E-cadherin is associated with high grade morphology of tumours and there is a significant inverse relation between E-cadherin expression and survival in some tumours.10–13 Normal cultured human melanocytes express both E-cadherin and P-cadherin, but it is E-cadherin that is primarily responsible for adhesion of melanocytes to keratinocytes.14 Transformed melanocytes produce reduced amounts of E-cadherin and exhibit decreased affinity for normal keratinocytes; a role for the loss of cadherin expression in melanoma metastasis has been suggested.14,15

Cadherins bind to unphosphorylated β or γ catenin, forming an E-cadherin or P-cadherin–catenin unit in the lateral cell membrane, functionally maintaining cell–cell contacts, and providing a link to the actin cytoskeleton through α catenin. A functional interaction has also been reported between phosphorylated β catenin and the transcription factors LEF-1 and Tcf-4, proving that there are mechanisms by which cell adhesion molecules can signal directly to the nucleus and potentially influence growth regulating signals. Of interest is the finding that when β catenin accumulates in the cytoplasm, as a result of mutations or otherwise, numbers of β catenin–Lef1 complexes also increase, with the potential for signal transduction16 and a role in melanoma progression.

Conflicting data have been published on cadherin expression in primary melanoma,17–19 and few reports have documented the expression of P-cadherin, β catenin, and γ catenin in melanocytic naevi and melanoma. Using immunohistochemistry on paraffin wax processed archival material, and tissue fractionation as well as western blotting of the proteins using fresh frozen metastatic melanoma tumour tissue, we aimed to assess the membranous expression of
the classic cadherins (E-cadherin, P-cadherin, and N-cadherin) and the desmosomal cadherin, desmoglein, during the progression of melanocytic tumours from dysplastic naevi to stage III metastatic melanoma. We also assessed whether alterations in catenin expression correlated with tumour biology.

Methods

tentions and Patients

Tissue was fixed routinely in 10% buffered formalin and processed through paraffin wax (Shandon PathCentre 16 hour cycle; Shandon, Runcorn, Cheshire, UK). Sections were cut and mounted on APES prepared slides (dried at 37°C overnight).

A dysplastic naevus was defined histologically as showing distinct cytological and architectural atypia with elongation of rete ridges and a host response in the dermis. Atypia was graded as mild, moderate, or severe, based on a published scoring system.18 Melanomas were allocated into radial or vertical growth phase according to published criteria.19 Numbers of cases were as follows: (1) dysplastic naevi (n = 30); (2) melanoma without metastasis, radial growth phase in situ (n = 10), radial growth phase microinvasive (n = 10), and vertical growth phase (n = 10); and (3) patients with a single “in transit” cutaneous, or small regional lymph node, metastasis (matched primary melanomas with the metastasis, n = 10). Using the TNM classification, no primary tumour was classified greater than pT3b and no secondary deposit greater than pN2b (that is, clinical stage III).

IMMUNOHISTOCHEMISTRY

Sections were microwave pretreated and immunostained using a standard indirect avidin–biotin complex (ABC) technique. The antibodies used were anti-E-cadherin (HECD-1; 1/100 dilution; Affiniti Research Products, Exeter, Devon, UK; anti-P-cadherin (1/50 dilution; Affiniti Research Products), anti-β catenin and anti-γ catenin (gifts from K Herrenknecht, University College London, EASAI Institute, UK; optimum dilution 1/10), antidesmoglein (against desmogleins 1 and 3; 1/5 dilution; gift from D Garrod, Institute of Biological Sciences, Manchester University, UK) and anti-N-cadherin (1/20 dilution; gift from MJ Wheelock, Department of Biology, University of Toledo, USA). All antibodies were used at concentrations between 0.5 and 3 µg/ml. The patterns of immunohistochemical staining (membranous or cytoplasmic) and the percentage of cells stained were noted for each sample by one of us (DSAS). In patients with metastatic disease, statistical comparisons were made for membranous immunoreactivity between the primary and metastatic melanomas. Tumours were allocated a score of 0–3, depending on the percentages of cells showing membranous immunoreactivity (0, no staining; 1, 1–50%; 2, 50–70%; 3, 70–100%). Data were analysed by non-parametric means using the Wilcoxon signed ranks test for related samples. The presence of epidermis in all of the skin lesions provided an inbuilt positive control for a membranous pattern of staining for all antibodies.
except for N-cadherin, where brain tissue was used as a control.

IMMUNOBLOTTING/TISSUE FRACTIONATION

To study the subcellular localisation of cadherins and catenins in more detail we used tissue fractionation and western blotting. An aliquot of 100 mg of fresh frozen tumour tissue from deposits of metastatic melanoma (n = 4) was homogenised in 1 ml 0.32 M sucrose, 5 mM Tris (pH 7.2), and protease inhibitor cocktail (Sigma, Poole, Dorset, UK). Tissue was spun at 5500 ×g for one hour. The supernatant was removed (cytoplasmic fraction). The pellet was resuspended in sucrose and protease inhibitors, re-centrifuged, and the supernatant discarded. The pellet was resuspended in 9 M urea, 50 mM Tris/Cl (pH 7.3), sonicated, and spun

Figure 2  (A) Membranous and strong cytoplasmic immunoreactivity of type A naevocytes with β catenin in a dysplastic naevus. Note the membranous positivity of the keratinocytes of the epidermis acting as an internal positive control. Magnification, ×400. (B) No immunoreactivity is seen in nests of type A naevocytes in a dysplastic naevus with γ catenin. Adjacent keratinocytes again act as a positive control. Magnification ×100.

Figure 3 Strong membranous immunoreactivity (100% of cells) with (A) E-cadherin and (B) P-cadherin in a primary vertical growth phase malignant melanoma. Magnification ×100.
at 15 000 xg for 10 minutes. The supernatant was removed (particulate/membranous fraction). Samples were balanced for protein content and 10 µg of each fraction was loaded on to a 10% sodium dodecyl sulphate (SDS) polyacrylamide gel and blotted for E-cadherin and P-cadherin (Transduction Laboratories, Lexington, USA) and β-catenin and γ-catenin (Santa Cruz Biotechnology, Santa Cruz, USA). Normal oesophageal squamous mucosa was used as a positive control.

Results

NORMAL CONTROLS

The pattern of immunoreactivity seen in the epidermis of normal skin was membranous staining of keratinocytes in the basal layer for P-cadherin and staining throughout the whole epidermal thickness for E-cadherin, β-catenin, γ-catenin, and desmoglein. A fibrillar pattern of immunoreactivity was seen in brain tissue for N-cadherin.

<table>
<thead>
<tr>
<th>Patient</th>
<th>E-cadherin (1°)</th>
<th>E-cadherin (2°)</th>
<th>P-cadherin (1°)</th>
<th>P-cadherin (2°)</th>
<th>β-Catenin (1°)</th>
<th>β-Catenin (2°)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>3</td>
<td>3</td>
<td>2</td>
<td>0</td>
<td>3</td>
<td>2</td>
</tr>
<tr>
<td>2</td>
<td>3</td>
<td>3</td>
<td>2</td>
<td>0</td>
<td>3</td>
<td>2</td>
</tr>
<tr>
<td>3</td>
<td>3</td>
<td>3</td>
<td>2</td>
<td>0</td>
<td>3</td>
<td>2</td>
</tr>
<tr>
<td>4</td>
<td>3</td>
<td>3</td>
<td>2</td>
<td>0</td>
<td>3</td>
<td>2</td>
</tr>
<tr>
<td>5</td>
<td>3</td>
<td>3</td>
<td>2</td>
<td>0</td>
<td>3</td>
<td>2</td>
</tr>
<tr>
<td>6</td>
<td>3</td>
<td>3</td>
<td>2</td>
<td>0</td>
<td>3</td>
<td>2</td>
</tr>
<tr>
<td>7</td>
<td>2</td>
<td>3</td>
<td>0</td>
<td>0</td>
<td>3</td>
<td>2</td>
</tr>
<tr>
<td>8</td>
<td>2</td>
<td>2</td>
<td>0</td>
<td>0</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>9</td>
<td>2</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>10</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>2</td>
<td>2</td>
</tr>
</tbody>
</table>

Tumours were allocated a staining score (0–3) depending on the percentage of cells with membranous immunoreactivity. There was no significant loss of membranous E-cadherin immunoreactivity between primary and secondary tumours (p < 0.257) using the Wilcoxon signed ranks test for related samples. Loss of membranous P-cadherin and β-catenin was significant (p < 0.014 and p < 0.005, respectively).

 Figures 4, 5, 6: Sample images showing immunoreactivity patterns.

DYSPLASTIC NAEVI

The pattern of immunoreactivity for each antibody in naevi and malignant melanomas is shown graphically in fig 1A–C. In dysplastic naevi, small senile intradermal naevus cells (type B melanocytes) were either negative or showed minimal cytoplasmic immunoreactivity for E-cadherin, P-cadherin, N-cadherin, β-catenin, and γ-catenin. Epithelioid junctional and intradermal melanocytes...
(type A melanocytes) showed universal (100% of cells) strong membranous E-cadherin and P-cadherin immunoreactivity, regardless of the degree of cytological atypia. However, they had predominantly synchronous membranous and cytoplasmic β catenin immunoreactivity (fig 2A). There was no discernible membranous N-cadherin, γ catenin (fig 2B), or desmoglein immunoreactivity (30 of 30 patients).

**PRIMARY RADIAL AND VERTICAL GROWTH PHASE MALIGNANT MELANOMA**

All junctional and intradermal cells of in situ (10 of 10 patients), microinvasive radial growth phase (10 of 10 patients), and vertical growth phase melanomas (10 of 10 patients) showed strong, predominantly membranous E-cadherin and P-cadherin immunoreactivity (fig 3A and B), and membranous or cytoplasmic β catenin immunoreactivity. However, no membranous N-cadherin, γ catenin, or desmoglein immunoreactivity was seen.

**MELANOMA WITH EARLY METASTASIS**

*Immunohistochemistry*

Table 1 gives details of the statistical analysis of the comparison of scores of membranous expression of E-cadherin and P-cadherin and β catenin in the primary and matched secondary (metastatic) melanomas in 10 patients.

Only six of 10 patients showed membranous P-cadherin immunoreactivity in the primary melanoma, with significant loss of membranous P-cadherin expression between primary and secondary melanomas (Z = −2.449; p < 0.014; table 1). No immunoreactivity was seen in primary or secondary melanomas in the remaining four patients. Strong membranous E-cadherin immunoreactivity was seen in all primary melanomas (10 of 10 patients). Six patients showed no change in expression between the primary and matched metastatic melanoma (fig 4), two patients showed minor membranous E-cadherin loss in the metastasis, two patients showed dramatic E-cadherin downregulation with loss of membranous expression in the metastasis, and there was membranous E-cadherin upregulation in one metastasis. This loss of membranous E-cadherin immunoreactivity between primary and secondary melanomas was not significant (Z = −1.134; p < 0.257; table 1). Minimal membranous N-cadherin immunoreactivity (1% of cells) was seen in three of 10 primary melanomas (fig 5), with striking N-cadherin expression in 70% of cells in one of 10 metastases. All other samples were negative.

There was significant loss of membranous β catenin expression between primary and metastatic melanomas (Z = −2.810; p < 0.005; table 1). Strong membranous β catenin immunoreactivity was seen in most cells in seven of the 10 primary melanomas. Loss of membranous expression was seen in all of the matched metastases (fig 6). Concomitant membranous and cytoplasmic expression was seen in the remaining three primary melanomas, with no change in two, and loss of membranous expression in one patient.

No γ catenin or desmoglein immunoreactivity was seen in any of the primary or secondary melanomas.

**Figure 7** Tissue fractionation and western blotting of normal squamous oesophageal mucosa (positive control; lanes 1 and 2) and four metastatic melanoma samples (lanes 3–10). The membranous cellular fractions were run in lanes with odd numbers and the cytoplasmic fractions in even numbered lanes. (A) As indicated by the arrow, the control and three melanoma samples show strong membranous immunoreactivity with E-cadherin (lanes 1, 3, 5, and 9). One sample shows concomitant cytoplasmic positivity (lane 10). One sample is negative (lanes 6 and 7). (B) As indicated by the arrow, the control and two samples show membranous β catenin immunoreactivity (lanes 1, 3, and 9), one also with concomitant cytoplasmic positivity (lane 10). Two samples are negative. (C) No positivity is seen in either cell fraction with γ catenin despite a positive membranous control.
Tissue fractionation and western blotting
More detailed subcellular localisation of cadherins and catenins was seen with tissue fractionation and western blotting. Immunoreactivity was seen in the membranous fraction only in the normal squamous mucosa, with E-cadherin, P-cadherin, β-catenin, and γ-catenin acting as a positive control. Three of four metastatic tumour samples showed strong E-cadherin expression in the membranous fraction, but only one of the three showed concomitant expression in the cytoplasmic fraction (fig 7A). Two samples showed strong membranous β-catenin expression, one with concomitant cytoplasmic expression (the same sample showed concomitant membranous and cytoplasmic E-cadherin expression), and two samples showed no β-catenin immunoreactivity in either cellular fraction (fig 7B). P-cadherin and γ-catenin (fig 7C) could not be demonstrated in either cellular fraction of the four samples.

Discussion
The study of the precursor lesions of metastatic malignant melanoma provides insights into the biological progression of these tumours. Our study on paraaffin wax processed material from surgically removed melanocytic tumours has shown that in dysplastic naevi, membranous expression of E-cadherin is related to melanocytic maturity and an epithelioid phenotype, regardless of grade of cytological atypia. In contrast to a recent publication, we show that the expression of membranous E-cadherin is largely maintained during malignant transformation to radial growth phase melanoma and with progression to vertical growth phase melanoma and metastasis. Thus, loss of E-cadherin expression is apparently not a universal or inevitable feature of tumour progression, as has been suggested. However, we did show significant derangement of P-cadherin expression; the appropriate membranous expression seen in primary vertical growth phase melanomas is significantly altered in metastatic tumours.

Although appropriate membranous E-cadherin expression in most malignant melanomas implies potential preservation of adhesive function, normal cadherin expression does not always equate to normal function, because function can be modified by both the specificity and amount of different cadherins on cell surfaces and cadherin glycosylation; in addition, it is dependent on intact binding with unphosphorylated catenins. Furthermore, one report has noted that melanomas express more types of novel cadherins than do melanocytes. In this respect, we have shown “de novo” expression of the neural cadherin, N-cadherin, in a small number of metastasising melanomas. N-cadherin has been found in contacts between melanoma cells in cell lines. Inappropriately expressed N-cadherin might compete with E-cadherin and P-cadherin for transmembrane binding with available catenins. A role for N-cadherin in the transendothelial migration of melanoma cells in culture has also been suggested.

It is of considerable interest that we have demonstrated aberrant β-catenin expression, with significant loss of membranous expression seen with progression to melanoma metastasis and inappropriate strong cytoplasmic immunoreactivity, in many dysplastic naevi and secondary melanomas. Early in the gastrulation stage of development, β-catenin and γ-catenin translocate to the nucleus and, in association with LEF-1 and Tcf, induce cells to form mobile mesodermal sheets, which are necessary for organogenesis. In normal tissues, β-catenin is usually bound to membranous cadherins or to the adenomatous polyposis coli (APC) gene product, where it is targeted for destruction. In melanomas, as in some other common tumours, during early cellular transformation the APC gene product might be mutated, thereby increasing the pool of cytoplasmic β-catenin with the potential for growth regulating signalling to the nucleus. Stabilisation of β-catenin is also seen after mutation of the β-catenin gene. Therefore, cytoplasmic β-catenin might be expected to be a feature of rapid tumour growth and biological aggression. In our study, cytoplasmic immunoreactivity was a frequent feature in dysplastic naevi and secondary melanomas, both proliferating and biologically active tumours, but was seen only rarely in radial growth phase melanomas—biologically indolent tumours that show little mitotic activity, no expansile growth, and lack the ability to metastasise. However, biological progression of melanoma to the vertical growth phase implies more expansile growth with cellular proliferation; surprisingly, the synthesis of cytoplasmic β-catenin was not a frequent feature of these tumours in our study. We saw no nuclear staining for β-catenin in our study, as has been reported recently in tumorigenesis in the oesophagus. It is noteworthy that tumour infiltrating lymphocytes have been shown recently to recognise an antigen encoded by a mutated human gene, namely, the β-catenin gene. This might provide new opportunities for therapeutic strategies against melanoma.

It is of interest that no membranous γ-catenin or desmoglein could be demonstrated in dysplastic naevi or melanomas. γ-Catenin is usually co-localised with β-catenin in epithelial tissues and tumours at cell junctions. Lack of γ-catenin would imply obligatory transmembrane binding of catenins to β-catenin for maintenance of adhesive function. γ-Catenin is unique in that it links both desmosomal and classic catenins to the cytoskeleton. Data on squamous epithelial cells suggest that γ-catenin must be linked to E-cadherin in the adherens junction before the cell can begin to assemble desmosomal components at regions of cell contact. In the absence of γ-catenin, adherens junctions can form using only β-catenin, but such junctions cannot support the formation of desmosomes. At the ultrastructural level, melanoma cells are reported to have no desmosomes and only rudimentary cell junctions, which might partly be the result of the absence of γ-catenin.
In conclusion, we have shown that the greatest changes in cadherin and catenin expression occur at the stage of metastasis of vertical growth phase melanoma, characterised by significant loss of membranous P-cadherin and β-catenin, minimal membranous E-cadherin loss, and minor de novo membranous N-cadherin expression. No membranous γ-catenin or desmoglein is seen in melanocytic tumours. These changes, together with cytoplasmic β-catenin expression in secondary melanomas, imply the loss of adhesive capacity, the potential for nuclear signalling, and hence a role for these cell adhesion molecules in the growth, invasion, and spread of malignant melanoma.

The authors thank M Wheelock for the kind donation of the antibody to N-cadherin used in this study.

Alterations in cadherin and catenin expression during the biological progression of melanocytic tumours.

D S Sanders, K Blessing, G A Hassan, R Bruton, J R Marsden and J Jankowski

Mol Path 1999 52: 151-157
doi: 10.1136/mp.52.3.151

Updated information and services can be found at:
http://mp.bmj.com/content/52/3/151

These include:

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes